|
Itopride (INN, trade name Ganaton) is a prokinetic benzamide derivative unlike metoclopramide or domperidone. These drugs inhibit dopamine and have a gastrokinetic effect. Itopride is indicated for the treatment of functional dyspepsia and other gastrointestinal conditions. Itopride is not currently approved by the U.S. Food and Drug Administration (FDA) for use in the United States, nor is it yet approved in the United Kingdom. This may explain the apparent lack of patient information available in ] compared to other similar classes of medication. == Clinical use == Typically, itopride is indicated in the treatment of GI symptoms caused by reduced GI motility: *dyspepsia of a non-ulcer/dysmotility type (gastric "fullness", discomfort, and possible pain)〔 *Delayed gastric emptying *anorexia *heartburn *regurgitation *bloating *nausea and vomiting *other possible gastric, prolactin, or dopamine related conditions Itopride is typically taken three times a day. The dose is usually taken on an empty stomach about an hour before meals. However, the dosage and details of administration may vary depending on the patient’s age, symptoms, and other factors. Itopride was shown to significantly improve symptoms in patients with functional dyspepsia and motility disorders in placebo-controlled trials. These studies concluded that the reduction in the severity of symptoms of functional dyspepsia after 8 weeks of treatment with itopride indicated that itopride was significantly superior to placebo and that itopride yielded a greater rate of response than placebo in significantly reducing pain and fullness. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Itopride」の詳細全文を読む スポンサード リンク
|